Showing results (141-150 of 158) with videos related to
Sort By:
Pageof 16
Cancer Research|April 6, 2007
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycinAlison Maloney, Paul A Clarke, Soren Naaby-Hansen, et al.European Journal of Cancer (Oxford, England : 1990)|August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trialHenk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.Oncotarget|October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysisMarion Savina, Saskia Litière, Antoine Italiano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studiesTimothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraPhilippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.The Lancet. Oncology|June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialIan Judson, James P Morden, Lucy Kilburn, et al.The Lancet. Oncology|March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Jaap Verweij, Hans Gelderblom, et al.European Journal of Cancer (Oxford, England : 1990)|January 4, 2023
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022Christian Rothermundt, Dimosthenis Andreou, Jean-Yves Blay, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Ewing Sarcoma: Current Management and Future Approaches Through CollaborationNathalie Gaspar, Douglas S Hawkins, Uta Dirksen, et al.Pageof 16